auceliciclib (AU3-14) / Aucentra, Qianhong Bio-Pharma - LARVOL DELTA

An interventional study to safety, tolerability (how well a substance is tolerated by patients), and Pharmacokinetics (PK, the measure of how the human body processes a substance) of different dosages of Auceliciclib when given to patients with advanced solid tumours as either the only treatment, or in patients with a specific type of cancer, Glioblastoma multiforme (GBM), when given together... (ANZCTR) - P1/2 | N=60 | Completed | Sponsor: Aucentra Therapeutics Pty Ltd. | Active, not recruiting ➔ Completed

Trial completion • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

An interventional study to safety, tolerability (how well a substance is tolerated by patients), and Pharmacokinetics (PK, the measure of how the human body processes a substance) of different dosages of Auceliciclib when given to patients with advanced solid tumours as either the only treatment, or in patients with a specific type of cancer, Glioblastoma multiforme (GBM), when given together... (ANZCTR) - P1/2 | N=60 | Active, not recruiting | Sponsor: Aucentra Therapeutics Pty Ltd. | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Metastases • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor